Italia markets closed

Nicox S.A. (0RCQ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,4045+0,0025 (+0,62%)
Alla chiusura: 02:51PM GMT

Nicox S.A.

2405 Route Des Dolines
Drakkar 2 Bât D
Valbonne 06560
France
33 4 97 24 53 00
https://www.nicox.com

Settore/i
Settore
Impiegati a tempo pieno28

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Michele Garufi Ph.D.Co-Founder & Director441,62kN/D1954
Dr. Gavin M. SpencerChief Executive OfficerN/DN/D1970
Ms. Sandrine GestinVice President of FinanceN/DN/D1967
Mr. Doug HubatschExecutive VP & Chief Scientific OfficerN/DN/D1967
Ms. Emmanuelle PierryGeneral Counsel & Head of Legal AffairsN/DN/D1969
Dr. Ramesh KrishnamoorthySenior Director and Head of Late Stage CMC & Quality ControlN/DN/DN/D
Dr. Jose BoyerConsultantN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

Governance aziendale

L'ISS Governance QualityScore di Nicox S.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.